Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Fludarabine/Melphalan vs Fludarabine/Melphalan Conditioning in Older AML/MDS Patients
NCT07396480Phase 3Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2026
- Primary completion
- Jan 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Mar 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07396480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396480.